Mann B D, Kern D H, Giuliano A E, Burk M W, Campbell M A, Kaiser L R, Morton D L
Arch Surg. 1982 Jan;117(1):33-6. doi: 10.1001/archsurg.1982.01380250019004.
We tested the ability of the in vitro clonogenic assay (CLAS) to predict clinical response for patients with solid tumors. Patients had objectively measurable disease and received at least one course of chemotherapy. The correlation between clinical responses and in vitro sensitivity was evaluated retrospectively. Tumor types included melanoma (19), sarcoma (five), hepatoma (one), and carcinoma of the stomach (two), colon (three), lung (one), and breast (one). Five patients received two separate courses of chemotherapy with different drugs or drug regimens. In nine of 11 (82%) instances, tumors were sensitive to a particular drug, and the patient had at least 50% regression of tumor following treatment with the tested drug. Two patients whose tumors were sensitive in vitro had no evidence of clinical response. In 25 of 26 assays, the CLAS accurately predicted tumor resistance, and only one patient had evidence of clinical response (96%). Associations of in vitro results with clinical responses were highly significant. The CLAS can accurately predict the chemosensitivity of a variety of solid tumors.
我们测试了体外克隆形成试验（CLAS）预测实体瘤患者临床反应的能力。患者患有可客观测量的疾病，并接受了至少一个疗程的化疗。回顾性评估临床反应与体外敏感性之间的相关性。肿瘤类型包括黑色素瘤（19例）、肉瘤（5例）、肝癌（1例）、胃癌（2例）、结肠癌（3例）、肺癌（1例）和乳腺癌（1例）。5名患者接受了两种不同药物或药物方案的单独化疗疗程。在11例中的9例（82%）中，肿瘤对特定药物敏感，并且患者在用测试药物治疗后肿瘤至少消退了50%。两名肿瘤在体外敏感的患者没有临床反应的证据。在26次试验中的25次中，CLAS准确预测了肿瘤耐药性，只有1名患者有临床反应的证据（96%）。体外结果与临床反应之间的关联非常显著。CLAS可以准确预测多种实体瘤的化学敏感性。
